「trial」の検索結果

Knowledge base from the DoD M&Q BoK (the Manufacturing and Quality Engineering Body of Knowledge), v3.0 of July 2025, published by OUSD(R&E). Use for the manufacturing-and-quality view of the defense acquisition life cycle: what M&Q engineers do across the Adaptive Acquisition Framework phases (Pre-MDD, Materiel Solution Analysis, Technology Maturation and Risk Reduction, Engineering and Manufacturing Development, Production and Deployment, Operations and Support); the twelve M&Q threads (A–L) built on the '5 Ms'; manufacturing feasibility and producibility; Manufacturing Readiness Levels and assessments; Key/Critical Characteristics and process capability (Cp/Cpk, SPC); the standards stack (AS6500, AS9100/ISO 9001, AS9103, AS9145); technical reviews (ASR/PDR/CDR/PRR) and milestone gates; DCMA surveillance; industrial base and supply chain; and sustainment (LCSP, IPS, ILA, ISR). Scope is DoD acquisition M&Q practice on the Major Capability Acquisition path — it is a best-practice compilation, not policy, and is thin on detailed shop-floor process engineering, contract law, and the full text of the cited industry standards (which it names but does not reproduce).

日本語の概要は準備中です。原文の説明を表示しています。

WooCommerce Memberships storage and relationship map for membership plan CPTs, user membership CPTs, post statuses, plan/user membership meta keys, rule storage, profile-field storage, order grant meta, and WooCommerce Subscriptions-linked memberships. Use when code reads or writes wc_membership_plan, wc_user_membership, wcm-* statuses, wc_memberships_rules, _subscription_id, _has_installment_plan, _free_trial_end_date, membership plan access meta, user membership dates, product/order grant meta, or when an agent needs exact Memberships CPT/meta names and the Memberships-Subscriptions relation.

日本語の概要は準備中です。原文の説明を表示しています。

Search the live web and 36+ specialised data sources including SEC filings, PubMed, ChEMBL, clinical trials, FRED economic indicators, and patent databases. Use when current, authoritative, or paywalled data is required.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end eval-suite orchestration with the `eval` command: run -> grade -> compare -> calibrate, using strict JSON contracts and schema discovery.

日本語の概要は準備中です。原文の説明を表示しています。

Build command-only adapters for `eval` run mode using strict stdin/stdout JSON contracts.

日本語の概要は準備中です。原文の説明を表示しています。

Use for agentic commerce payments tasks. Candidate synthesized from trend radar; awaiting trial promotion.

日本語の概要は準備中です。原文の説明を表示しています。

Use for enterprise agent deployment tasks. Candidate synthesized from trend radar; awaiting trial promotion.

日本語の概要は準備中です。原文の説明を表示しています。

Pull design principles from architecture, fashion, film, industrial design, and physical spaces into screen-based design. Use when seeking inspiration beyond digital, expanding creative range, or building cross-disciplinary design vocabulary.

日本語の概要は準備中です。原文の説明を表示しています。

Draw from architecture, fashion, music, food, and industrial design to expand your design taste range. Use when seeking inspiration beyond digital, building diverse reference sets, or expanding creative vocabulary.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to analyze their own app's actual performance data from App Store Connect — real downloads, revenue, IAP, subscriptions, trials, or country breakdowns synced via Appeeky Connect. Use when the user asks about "my downloads", "my revenue", "how is my app performing", "ASC data", "sales and trends", "my subscription numbers", "App Store Connect metrics", or wants to compare periods or top markets. For third-party app estimates, see app-analytics. For subscription analytics depth, see monetization-strategy.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to design or optimize their app's monetization — pricing, paywalls, subscriptions, or in-app purchases. Also use when the user mentions "pricing", "paywall", "subscription", "IAP", "how to monetize", "revenue optimization", "free trial", or "conversion to paid". For retention impact, see retention-optimization. For competitive pricing, see competitor-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants help with pricing decisions, packaging, or monetization strategy. Also use when the user mentions 'pricing,' 'pricing tiers,' 'freemium,' 'free trial,' 'packaging,' 'price increase,' 'value metric,' 'Van Westendorp,' 'willingness to pay,' or 'monetization.' This skill covers pricing research, tier structure, and packaging strategy.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to create or optimize in-app paywalls, upgrade screens, upsell modals, or feature gates. Also use when the user mentions "paywall," "upgrade screen," "upgrade modal," "upsell," "feature gate," "convert free to paid," "freemium conversion," "trial expiration screen," "limit reached screen," "plan upgrade prompt," or "in-app pricing." Distinct from public pricing pages (see page-cro) — this skill focuses on in-product upgrade moments where the user has already experienced value.

日本語の概要は準備中です。原文の説明を表示しています。

This skill covers detecting sophisticated cyber-physical attacks that follow the Stuxnet attack pattern of modifying PLC logic while spoofing sensor readings to hide the manipulation from operators. It addresses PLC logic integrity monitoring, physics-based process anomaly detection, engineering workstation compromise indicators, USB-borne attack vectors, and multi-stage attack chain detection spanning IT-to-OT lateral movement through to process manipulation.

日本語の概要は準備中です。原文の説明を表示しています。

Estimates the minimum biological replicates (or cells/events) for a target power at a target FDR in genomics experiments using ssizeRNA, PROPER, powsimR for scRNA-seq, and pilot-data dispersion estimation from DESeq2/edgeR. Covers the biological-versus-technical replication distinction (technical replicates do not add degrees of freedom for biological inference), replicate-number-versus-sequencing-depth budgeting, scRNA-seq sample-versus-cell allocation under a pseudobulk model, and the critique that "n=3" is a publication convention rather than a power calculation. Use when budgeting a sequencing experiment, writing the sample-size justification in a grant, estimating replicates from pilot data, allocating a fixed budget between samples and depth, or planning scRNA-seq cohort size. For clinical-trial sample size see clinical-biostatistics/power-and-sample-size; for the power-given-n direction see experimental-design/power-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Build Sankey, alluvial, river, and CONSORT-style flow diagrams to visualize cohort transitions, cell-state changes, or pipeline filtering using ggalluvial, networkD3, plotly, and consort. Use when showing how entities move between categories across timepoints (cell states, drug response classes, patient flow through a trial) or filtering pipelines (variants filtered through QC stages).

日本語の概要は準備中です。原文の説明を表示しています。

Build forest plots (HR, OR, RR, beta-coefficient summaries with CIs) and funnel plots (meta-analysis publication-bias diagnostics) using forestplot, metafor, ggforest, and MendelianRandomization with proper axis-scaling, summary-diamond placement, subgroup nesting, and Egger / trim-and-fill asymmetry tests. Use when summarizing effects across subgroups, trials, or instruments — meta-analysis, Mendelian randomization, subgroup HRs.

日本語の概要は準備中です。原文の説明を表示しています。

Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Statistical modeling — linear/logistic/ordinal/Poisson regression, ANOVA, Kruskal-Wallis, chi-square, Mann-Whitney, Cox survival, spline fits (R `ns()`), odds ratios, Cohen's d, F-statistic, p-value computation. Specializes in clinical-trial AE analysis (SDTM DM/AE), severity ordinal regression, and per-feature stat workflows.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.

日本語の概要は準備中です。原文の説明を表示しています。

Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).

日本語の概要は準備中です。原文の説明を表示しています。